References

Leading progress in heart regeneration and repair

10.1016/j.ceb.2019.07.005 · 2019 · External reference

Global trends in atherosclerotic cardiovascular disease

10.1016/j.clinthera.2023.09.020 · 2023 · External reference

Review on emerging therapeutic strategies for managing cardiovascular disease

10.2174/011573403x299265240405080030 · 2024 · External reference

Induced pluripotent stem cells for cardiovascular disease modeling and precision medicine

10.1161/hcg.0000000000000043 · 2018 · External reference

Human induced pluripotent stem cell as a disease modeling and drug development platform—a cardiac perspective

10.3390/cells10123483 · 2021 · External reference

A concise review on induced pluripotent stem cell-derived cardiomyocytes for personalized regenerative medicine

10.1007/s12015-020-10061-2 · 2021 · External reference

Concise review: harnessing iPSC-derived cells for ischemic heart disease treatment

10.2478/jtim-2020-0004 · 2020 · External reference

Induced pluripotent stem cell-derived smooth muscle cells to study cardiovascular calcification

10.3389/fcvm.2022.925777 · 2022 · External reference

Murine “model” monotheism

10.1161/circresaha.115.307523 · 2015 · External reference

Induced pluripotent stem cells: at the heart of cardiovascular precision medicine

10.1038/nrcardio.2016.36 · 2016 · External reference

Human iPSC modeling of heart disease for drug development

10.1016/j.chembiol.2021.02.016 · 2021 · External reference

Advances in stem cell modeling of dystrophin-associated disease: implications for the wider world of dilated cardiomyopathy

10.3389/fphys.2020.00368 · 2020 · External reference

Searching for an experimental rodent model of heart failure with preserved ejection fraction: re-visited

10.1016/j.biopha.2022.113251 · 2022 · External reference

Human induced pluripotent stem cell-derived cardiomyocytes to study inflammation-induced aberrant calcium transient

10.7554/elife.95867 · 2024 · External reference

Use of human induced pluripotent stem cell–derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing

10.1161/res.0000000000000291 · 2019 · External reference

The impact of CRISPR/Cas9 technology on cardiac research: from disease modelling to therapeutic approaches

10.1155/2017/8960236 · 2017 · External reference

Pre-clinical evaluation of the efficacy and safety of human induced pluripotent stem cell-derived cardiomyocyte patch

10.1186/s13287-024-03690-8 · 2024 · External reference

Unlocking personalized biomedicine and drug discovery with human induced pluripotent stem cell–derived cardiomyocytes: fit for purpose or forever elusive?

10.1146/annurev-pharmtox-010919-023309 · 2020 · External reference

Why 90% of clinical drug development fails and how to improve it?

10.1016/j.apsb.2022.02.002 · 2022 · External reference

Can the pharmaceutical industry reduce attrition rates?

10.1038/nrd1470 · 2004 · External reference

Reengineering an antiarrhythmic drug using patient hiPSC cardiomyocytes to improve therapeutic potential and reduce toxicity

10.1016/j.stem.2020.08.003 · 2020 · External reference

Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells

10.1016/j.celrep.2014.09.055 · 2014 · External reference

MAP4K4 inhibition promotes survival of human stem cell-derived cardiomyocytes and reduces infarct size in vivo

10.1016/j.stem.2019.01.013 · 2019 · External reference

CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy

10.1093/eurheartj/ehy249 · 2018 · External reference

How to improve R&D productivity: the pharmaceutical industry's grand challenge

10.1038/nrd3078 · 2010 · External reference

Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company

10.1101/cshperspect.a014092 · 2014 · External reference

An analysis of the attrition of drug candidates from four major pharmaceutical companies

10.1038/nrd4609 · 2015 · External reference

Evolution of strategies to improve preclinical cardiac safety testing

10.1038/nrd.2015.34 · 2016 · External reference

When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis

10.1371/journal.pone.0147215 · 2016 · External reference

High throughput physiological screening of iPSC-derived cardiomyocytes for drug development

10.1016/j.bbamcr.2016.03.003 · 2016 · External reference

High throughput measurement of Ca2+ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry

10.1016/j.vascn.2012.08.167 · 2012 · External reference

An automated platform for assessment of congenital and drug-induced arrhythmia with hiPSC-derived cardiomyocytes

10.3389/fphys.2017.00766 · 2017 · External reference

MUSCLEMOTION

10.1161/circresaha.117.312067 · 2018 · External reference

Recent technological advancements in traction force microscopy

10.1007/s12551-019-00589-0 · 2019 · External reference

HiPSCs derived cardiac cells for drug and toxicity screening and disease modeling: what micro- electrode-array analyses can tell us

10.3390/cells8111331 · 2019 · External reference

High-throughput screening to identify chemical Cardiotoxic potential

10.1021/acs.chemrestox.0c00382 · 2021 · External reference

In-depth mechanistic analysis including high-throughput RNA sequencing in the prediction of functional and structural cardiotoxicants using hiPSC cardiomyocytes

10.1080/17425255.2023.2273378 · 2024 · External reference

Mechanism of Block and identification of the verapamil binding domain to HERG potassium channels

10.1161/01.res.84.9.989 · 1999 · External reference

Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells

10.1038/s41598-020-62344-w · 2020 · External reference

Computational determination of hERG-related cardiotoxicity of drug candidates

10.1186/s12859-019-2814-5 · 2019 · External reference

Identifying acute cardiac Hazard in early drug discovery using a calcium transient high-throughput assay in human-induced pluripotent stem cell-derived cardiomyocytes

10.3389/fphys.2022.838435 · 2022 · External reference

Assessing drug-induced mitochondrial toxicity in cardiomyocytes: implications for preclinical cardiac safety evaluation

10.3390/pharmaceutics14071313 · 2022 · External reference

Promotion of maturation of human pluripotent stem cell-derived cardiomyocytes via treatment with the peroxisome proliferator-activated receptor alpha agonist Fenofibrate

10.1093/stcltm/szae029 · 2024 · External reference

Generation and maturation of human iPSC-derived 3D organotypic cardiac microtissues in long-term culture

10.1038/s41598-022-22225-w · 2022 · External reference

Investigating inherited heart diseases using human induced pluripotent stem cell-based models

10.3390/life14111370 · 2024 · External reference

IPSC-derived cardiomyocytes in inherited cardiac arrhythmias: pathomechanistic discovery and drug development

10.3390/biomedicines11020334 · 2023 · External reference

Modeling mutation-specific arrhythmogenic phenotypes in isogenic human iPSC-derived cardiac tissues

10.1038/s41598-024-52871-1 · 2024 · External reference

iPSC-based modeling of variable clinical presentation in hypertrophic cardiomyopathy

10.1161/circresaha.122.321951 · 2023 · External reference

An update on MYBPC3 gene mutation in hypertrophic cardiomyopathy

10.3390/ijms241310510 · 2023 · External reference

Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment

2023 · External reference

hiPSC MODELING OF INHERITED CARDIOMYOPATHIES

10.1007/s11936-014-0320-7 · 2014 · External reference

Modelling inherited cardiac disease using human induced pluripotent stem cell-derived cardiomyocytes: progress, pitfalls, and potential

10.1093/cvr/cvy208 · 2018 · External reference

A precision medicine approach to the Rescue of Function on malignant Calmodulinopathic long QT syndrome

10.1161/circresaha.116.309283 · 2017 · External reference

Human iPSC-derived cardiomyocytes for investigation of disease mechanisms and therapeutic strategies in inherited arrhythmia syndromes: strengths and limitations

10.1007/s10557-017-6735-0 · 2017 · External reference

Targeted activation of human ether-à-go-go-related gene channels rescues electrical instability induced by the R56Q+/− long QT syndrome variant

10.1093/cvr/cvad155 · 2023 · External reference

Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy

10.1093/europace/euy042 · 2018 · External reference

Increased cytosolic calcium buffering contributes to a cellular arrhythmogenic substrate in iPSC-cardiomyocytes from patients with dilated cardiomyopathy

10.1007/s00395-022-00912-z · 2022 · External reference

Spatiotemporal cell junction assembly in human iPSC-CM models of arrhythmogenic cardiomyopathy

10.1016/j.stemcr.2023.07.005 · 2023 · External reference

Mutant ANP induces mitochondrial and ion channel remodeling in a human iPSC–derived atrial fibrillation model

10.1172/jci.insight.155640 · 2022 · External reference

Studying long QT syndrome caused by NAA10 genetic variants using patient-derived induced pluripotent stem cells

10.1161/circulationaha.122.061864 · 2023 · External reference

Maturation of human cardiac organoids enables complex disease modeling and drug discovery

10.1038/s44161-025-00669-3 · 2025 · External reference

Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease

10.1016/j.stem.2020.05.004 · 2020 · External reference

Pluripotent stem cell-derived cardiomyocytes as a platform for cell therapy applications: Progress and hurdles for clinical translation

10.1016/j.ymthe.2018.02.026 · 2018 · External reference

Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes

10.1016/j.stem.2024.01.007 · 2024 · External reference

Pluripotent stem cell-based cardiac regenerative therapy for heart failure

10.1016/j.yjmcc.2023.12.001 · 2024 · External reference

Co-transplantation of mesenchymal stromal cells and induced pluripotent stem cell-derived cardiomyocytes improves cardiac function after myocardial damage

10.3389/fcvm.2021.794690 · 2022 · External reference

Stem cell-based therapy in cardiac repair after myocardial infarction: promise, challenges, and future directions

10.1016/j.yjmcc.2023.12.009 · 2024 · External reference

Development of composite functional tissue sheets using hiPSC-CMs and hADSCs to improve the cardiac function after myocardial infarction

2024 · External reference

4D physiologically adaptable cardiac patch: a 4-month in vivo study for the treatment of myocardial infarction

10.1126/sciadv.abb5067 · 2020 · External reference

Designing a 3D printing based auxetic cardiac patch with hiPSC-CMs for heart repair

10.3390/jcdd8120172 · 2021 · External reference

In vitro matured human pluripotent stem cell–derived cardiomyocytes form grafts with enhanced structure and function in injured hearts

10.1161/circulationaha.121.053563 · 2022 · External reference

Safety confirmation of induced pluripotent stem cell-derived cardiomyocyte patch transplantation for ischemic cardiomyopathy: first three case reports

10.3389/fcvm.2023.1182209 · 2023 · External reference

Combined treatment of human iPSC-derived cardiomyocytes and endothelial cells regenerate the infarcted heart in mice and non-human primates

10.1161/circulationaha.122.061736 · 2023 · External reference

Transplantation of human induced pluripotent stem cell-derived cardiomyocytes improves myocardial function and reverses ventricular remodeling in infarcted rat hearts

10.1186/s13287-020-01602-0 · 2020 · External reference

Transient secretion of VEGF protein from transplanted hiPSC-CMs enhances engraftment and improves rat heart function post MI

10.1016/j.ymthe.2022.08.012 · 2023 · External reference

Thymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell-derived cardiomyocytes in a porcine model of acute myocardial infarction

10.7150/thno.56757 · 2021 · External reference

Cardiac muscle patches containing four types of cardiac cells derived from human pluripotent stem cells improve recovery from cardiac injury in mice

10.1093/cvr/cvad004 · 2023 · External reference

CHIR99021 and fibroblast growth factor 1 enhance the regenerative potency of human cardiac muscle patch after myocardial infarction in mice

10.1016/j.yjmcc.2020.03.003 · 2020 · External reference

Spatiotemporal relation between gap junctions and fascia adherens junctions during postnatal development of human ventricular myocardium

10.1161/01.cir.90.2.713 · 1994 · External reference

Evidence for cardiomyocyte renewal in humans

10.1126/science.1164680 · 2009 · External reference

Engineering adolescence: maturation of human pluripotent stem cell–derived cardiomyocytes

10.1161/circresaha.114.300558 · 2014 · External reference

A brief review of current maturation methods for human induced pluripotent stem cells-derived cardiomyocytes

10.3389/fcell.2020.00178 · 2020 · External reference

Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure

10.1111/j.1582-4934.2011.01417.x · 2011 · External reference

Calcium signalling of human pluripotent stem cell-derived cardiomyocytes

10.1113/jphysiol.2013.256495 · 2013 · External reference

Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories

10.1016/j.yjmcc.2015.05.003 · 2015 · External reference

Single-cell resolution of temporal gene expression during heart development

10.1016/j.devcel.2016.10.001 · 2016 · External reference

Comparative gene expression analysis of mouse and human cardiac maturation

10.1016/j.gpb.2016.04.004 · 2016 · External reference

Excitation–contraction coupling of human induced pluripotent stem cell-derived cardiomyocytes

10.3389/fcell.2015.00059 · 2015 · External reference

Human induced pluripotent stem cell–derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes

10.1161/circresaha.117.305365 · 2015 · External reference

Structural immaturity of human iPSC-derived cardiomyocytes: in silico investigation of effects on function and disease modeling

10.3389/fphys.2018.00080 · 2018 · External reference

Sarcomeric protein isoform transitions in cardiac muscle: a journey to heart failure

10.1016/j.bbadis.2014.11.003 · 2015 · External reference

Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform

10.1016/j.bbamcr.2015.10.014 · 2016 · External reference

Metabolism of the heart in health and disease. Part I

10.1016/0002-8703(68)90168-3 · 1968 · External reference

Maturation of pluripotent stem cell-derived cardiomyocytes: limitations and challenges from metabolic aspects

10.1186/s13287-024-03961-4 · 2024 · External reference

Glycolysis is predominant source of myocardial ATP production immediately after birth

10.1152/ajpheart.1991.261.6.h1698 · 1991 · External reference

3D aggregate culture improves metabolic maturation of human pluripotent stem cell derived cardiomyocytes

10.1002/bit.26504 · 2018 · External reference

Metabolic substrate shift in human induced pluripotent stem cells during cardiac differentiation: functional assessment using in vitro radionuclide uptake assay

10.1016/j.ijcard.2018.06.089 · 2018 · External reference

Contractile work contributes to maturation of energy metabolism in hiPSC-derived cardiomyocytes

10.1016/j.stemcr.2018.01.039 · 2018 · External reference

Maturation strategies and limitations of induced pluripotent stem cell-derived cardiomyocytes

10.1042/bsr20200833 · 2021 · External reference

Cardiac excitation–contraction coupling

10.1038/415198a · 2002 · External reference

Phenotypic assays for analyses of pluripotent stem cell–derived cardiomyocytes

10.1002/jmr.2602 · 2017 · External reference

Switch from fetal to adult SCN5A isoform in human induced pluripotent stem cell–derived cardiomyocytes unmasks the cellular phenotype of a conduction disease–causing mutation

10.1161/jaha.116.005135 · 2017 · External reference

Ionic channels in excitable membranes. Current problems and biophysical approaches

10.1016/s0006-3495(78)85489-7 · 1978 · External reference

Amiodarone reduces transmural heterogeneity of repolarization in the human heart

10.1016/s0735-1097(98)00330-1 · 1998 · External reference

Mechanisms of cardiac arrhythmias

10.1016/j.joa.2015.11.003 · 2016 · External reference

Functional cardiomyocytes derived from human induced pluripotent stem cells

10.1161/circresaha.108.192237 · 2009 · External reference

High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents

10.1152/ajpheart.00694.2011 · 2011 · External reference

Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias

10.3389/fphys.2012.00346 · 2012 · External reference

Mechanism-based facilitated maturation of human pluripotent stem cell–derived cardiomyocytes

10.1161/circep.111.973420 · 2013 · External reference

Cardiac connexins and impulse propagation

10.1016/j.yjmcc.2009.08.018 · 2010 · External reference

Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell–derived cardiac myocyte monolayers

10.1161/circresaha.111.262535 · 2012 · External reference

Cardiomyocyte differentiation of human induced pluripotent stem cells

10.1161/circulationaha.109.868885 · 2009 · External reference

Larger cell size in rabbits with heart failure increases myocardial conduction velocity and QRS duration

10.1161/circulationaha.105.565804 · 2006 · External reference

Basic mechanisms of cardiac impulse propagation and associated arrhythmias

10.1152/physrev.00025.2003 · 2004 · External reference

Research progress towards the effects of fatty acids on the differentiation and maturation of human induced pluripotent stem cells into cardiomyocytes

10.31083/j.rcm2403069 · 2023 · External reference

Fatty acids enhance the maturation of cardiomyocytes derived from human pluripotent stem cells

10.1016/j.stemcr.2019.08.013 · 2019 · External reference

Culture in glucose-depleted medium supplemented with fatty acid and 3,3′,5-Triiodo-l-Thyronine facilitates purification and maturation of human pluripotent stem cell-derived cardiomyocytes

10.3389/fendo.2017.00253 · 2017 · External reference

Inhibition of fatty acid oxidation enables heart regeneration in adult mice

10.1038/s41586-023-06585-5 · 2023 · External reference

Promotion of maturation in CDM3-induced embryonic stem cell-derived cardiomyocytes by palmitic acid

2024 · External reference

Distinct carbon sources affect structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells

10.1038/s41598-017-08713-4 · 2017 · External reference

Metabolic maturation media improve physiological function of human iPSC-derived cardiomyocytes

10.1016/j.celrep.2020.107925 · 2020 · External reference

Effects of docosahexaenoic acid or arachidonic acid supplementation on the behavior of cardiomyocytes derived from human pluripotent stem cells

10.32604/biocell.2023.028186 · 2023 · External reference

Independent compartmentalization of functional, metabolic, and transcriptional maturation of hiPSC-derived cardiomyocytes

10.1016/j.celrep.2024.114160 · 2024 · External reference

TFPa/HADHA is required for fatty acid beta-oxidation and cardiolipin re-modeling in human cardiomyocytes

10.1038/s41467-019-12482-1 · 2019 · External reference

Metabolic environment in vivo as a blueprint for differentiation and maturation of human stem cell-derived cardiomyocytes

10.1016/j.bbadis.2020.165881 · 2020 · External reference

Small molecule-mediated rapid maturation of human induced pluripotent stem cell-derived cardiomyocytes

10.1186/s13287-022-03209-z · 2022 · External reference

AKAP1 regulates mitochondrial dynamics during the fatty-acid-promoted maturation of human-induced pluripotent stem cell-derived cardiomyocytes as indicated by proteomics sequencing

10.3390/ijms24098112 · 2023 · External reference

Thyroid hormone plays an important role in cardiac function: from bench to bedside

10.3389/fphys.2021.606931 · 2021 · External reference

Recent advances in regulating the proliferation or maturation of human-induced pluripotent stem cell-derived cardiomyocytes

10.1186/s13287-023-03470-w · 2023 · External reference

Thyroid hormone action in postnatal heart development

10.1016/j.scr.2014.07.001 · 2014 · External reference

Thyroid hormone SIGNALLING and consequences for cardiac development

10.1530/joe-18-0704 · 2019 · External reference

Tri-iodo-L-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells

10.1016/j.yjmcc.2014.04.005 · 2014 · External reference

Glucocorticoid signaling in the heart: a cardiomyocyte perspective

10.1016/j.jsbmb.2015.03.009 · 2015 · External reference

The glucocorticoid receptor in cardiovascular health and disease

10.3390/cells8101227 · 2019 · External reference

Glucocorticoids promote structural and functional maturation of foetal cardiomyocytes: a role for PGC-1α

10.1038/cdd.2014.181 · 2015 · External reference

Thyroid and glucocorticoid hormones promote functional T-tubule development in human-induced pluripotent stem cell derived cardiomyocytes

10.1161/circresaha.117.311920 · 2017 · External reference

Advancing cardiovascular tissue engineering

10.12688/f1000research.8237.1 · 2016 · External reference

Advances in 3D bioprinted cardiac tissue using stem cell-derived cardiomyocytes

10.1093/stcltm/szae014 · 2024 · External reference

Therapeutic strategies of three-dimensional stem cell spheroids and organoids for tissue repair and regeneration

2022 · External reference

Current methods for fabricating 3D cardiac engineered constructs

10.1016/j.isci.2022.104330 · 2022 · External reference

Three-dimensional poly-(ε-Caprolactone) Nanofibrous scaffolds promote the maturation of human pluripotent stem cells-induced cardiomyocytes

2022 · External reference

A three-dimensional culture system for generating cardiac spheroids composed of cardiomyocytes, endothelial cells, smooth-muscle cells, and cardiac fibroblasts derived from human induced-pluripotent stem cells

10.3389/fbioe.2022.908848 · 2022 · External reference

Current research trends and challenges in tissue engineering for mending broken hearts

10.1016/j.lfs.2019.05.012 · 2019 · External reference

Recent advances in tissue-engineered cardiac scaffolds—the progress and gap in mimicking native myocardium mechanical behaviors

10.3390/jfb14050269 · 2023 · External reference

Biomanufacturing of a chitosan/collagen scaffold to drive adhesion and alignment of human cardiomyocyte derived from stem cells

10.1016/j.procir.2015.09.004 · 2016 · External reference

Maturation of human iPSC-derived cardiac microfiber with electrical stimulation device

2024 · External reference

Electroconductive biomaterials for cardiac tissue engineering

10.1016/j.actbio.2021.08.031 · 2022 · External reference

Recent advances in designing electroconductive biomaterials for cardiac tissue engineering

10.1002/adhm.202200055 · 2022 · External reference

Advancements in tissue engineering for cardiovascular health: a biomedical engineering perspective

10.3389/fbioe.2024.1385124 · 2024 · External reference

Artificial scaffolds in cardiac tissue engineering

10.3390/life12081117 · 2022 · External reference

Bioresorbable polymeric scaffold in cardiovascular applications

10.3390/ijms21103444 · 2020 · External reference

Metabolically driven maturation of human induced pluripotent stem cell derived cardiac microphysiological systems

10.1038/s41551-022-00884-4 · 2022 · External reference

Human perinatal stem cell derived extracellular matrix enables rapid maturation of hiPSC-CM structural and functional phenotypes

10.1038/s41598-020-76052-y · 2020 · External reference

Cardiac ultrastructure inspired matrix induces advanced metabolic and functional maturation of differentiated human cardiomyocytes

10.1016/j.celrep.2022.111146 · 2022 · External reference

Engineered microenvironments for maturation of stem cell derived cardiac myocytes

10.7150/thno.19441 · 2018 · External reference

The harder the climb the better the view: the impact of substrate stiffness on cardiomyocyte fate

10.1016/j.yjmcc.2022.02.001 · 2022 · External reference

Extracellular matrix–mediated maturation of human pluripotent stem cell–derived cardiac monolayer structure and electrophysiological function

10.1161/circep.113.003638 · 2016 · External reference

Engineering of mature human induced pluripotent stem cell-derived cardiomyocytes using substrates with multiscale topography

2018 · External reference

Architecture design and advanced manufacturing of heart-on-a-chip: scaffolds, stimulation and sensors

10.1038/s41378-024-00692-7 · 2024 · External reference

Microstripe pattern substrate consisting of alternating planar and nanoprotrusive regions improved hiPSC-derived cardiomyocytes' unidirectional alignment and functional properties

10.1088/1748-605x/ad525d · 2024 · External reference

Induced pluripotent stem cell-derived cardiomyocytes: from regulatory status to clinical translation

10.1089/ten.teb.2023.0080 · 2024 · External reference

Efficient and reproducible generation of human iPSC-derived cardiomyocytes and cardiac organoids in stirred suspension systems

10.1038/s41467-024-50224-0 · 2024 · External reference